Learn how IV glutathione may help with inflammation
Thromboembolic disorder, a condition where blood clots form in the blood vessels 5
Metabolic syndrome: bridging the gap from childhood to adulthood
Injectable BPC-157 The injectable form delivers a precise, therapeutic dose and is often recommended for more targeted or intensive recovery support
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8
The applied wellness research with peptides page, for example, discusses how investigators are structuring experiments that combine tools such as BPC-157, TB-500, BPC capsules, and GLP pathway peptides